Mie University

Takara Bio Inc.

Kyoto University

Daiichi Sankyo Company, Limited

Daicel Corporation

Kabushiki Kaisha Yakult Honsha

General Incorporated Association Pharma Valley Project Supporting Organization

Immunofrontier, Inc.

Hiroshi Shiku

Junichi Mineno

Ikunoshin Kato

Yoshihiro Miyahara

Atsunori Hiasa

Satoshi Okumura

Hiroaki Naota

Hiroaki Ikeda

Kazunari Akiyoshi

Sachiko Okamoto

Naozumi Harada

Yasushi Akahori

Kensuke Nakamura

Ryuji Hashimoto

Toshiaki Ohtsuka

Ichiro Watanabe

Masanari Kitagawa

Makiko Nakayama

Naoya Shinozaki

Kento Tanaka

Shiho Kozuma

Junya Ichikawa

Daisuke Muraoka

Naohiro Seo

Ayaka Yatsu

Shinji Furuzono

Koichi Iwamura

Risa Sumioka

Jun Mitsui

Yuki Takenaka

Yuzo Yamamoto

Takaya Masumoto

Akira Asai

Naohisa Ogo

Yuki Orito

Yuya Kato

Tsuguhiro Kaneda

Junko Nakamura

Fumiyasu Momose

Yasunori Amaishi

Hiroshi Miwa

Koichi Furukawa

Keiko Furukawa

Hiroshi Fujiwara

Yuhsuke Ohmi

An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.

Bispecific antibody

A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.

The disclosure provides a method for preparing exosomes using: (i) a step for ultrafiltering a sample containing at least one exosome; and (ii) a step for subjecting the sample that can be obtained from step (i) to anion exchange column chromatography.

Exosome production method

CAR-T cells for cancer therapy are provided with an antibody that recognizes the MAGE-A4-derived-peptide/HLA-A2 complex. The antibody includes the VH amino acid sequence of SEQ ID NO: 36 and the VL amino acid sequence of SEQ ID NO: 38. The antibody preferably is provided with the amino acid sequence of SEQ ID NO: 32. Such CAR-T cells can be used in CAR infusion therapy in which a cancer-specific intracellular antigen is used.

Antigen-binding protein that recognizes MAGE-A4-derived peptide

To provide an agent for overcoming immunosuppression which can overcome immunosuppression by regulatory T cells. An agent for overcoming immunosuppression and an inhibitor of FOXP3 function containing an anthracycline antibiotic as an active ingredient.

Agent for overcoming immunosuppression and use thereof

A long-chain peptide antigen includes a plurality of epitopes. An interepitope sequence located between two of the plurality of epitopes contains four to ten consecutive tyrosines. The long-chain peptide antigen may be administered to a patient together with a hydrophobized polysaccharide, such as cholesterol-modified pullulan, and/or an adjuvant, such as CpG oligo DNA.

Long chain antigen containing interepitope sequence that promotes antigen presentation to T cells

Therapeutic agents effective for treating cell-proliferative diseases contain extracellular vesicles (exosomes) released from cytotoxic T cells or miRNA obtained from extracellular vesicles (exosomes) released from cytotoxic T cells, such as human CD8+ T cells. Such therapeutic agents suppress the proliferation of mesenchymal cells surrounding cancer cells, e.g., by killing the mesenchymal cells, such that the cancer cells become isolated and unable to metastasize. Cell-proliferative diseases are thus treatable by administering such a therapeutic agent to a patient.

Therapeutic agent associated with suppression of proliferation and metastasis of tumor, which comprises exosomes released from cytotoxic T cells and targets cancer stromal/mesenchymal cells

A needleless injector which can selectively induce the immune response and a method for introducing DNA including a region coding for an antigen to selectively produce an antibody in a living body of a mammal by using the needleless injector are provided. Disclosed is a needleless injector for injecting a DNA solution into an injection target area without using any injection needles. The needleless injector includes an accommodating unit which accommodates the DNA solution, a predetermined ignition device; and a predetermined nozzle unit. A temperature of the predetermined combustion product, which is provided during the pressurization, changes to a neighborhood of ordinary temperature within 20 msec after a pressure, which is applied to the DNA solution on account of the combustion of the igniter powder, reaches an initial peak discharge force during a pressurization process for discharging the DNA solution.

Needleless syringe and method for introducing DNA into injection target area using same

Disclosed is a method for enhancing the function of a T cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (PD-L1) and/or programmed death-1 ligand 2 (PD-L2) in the T cell. Also disclosed is a function-enhanced T cell which is produced by the function enhancement method. Further disclosed is a therapeutic agent comprising the function-enhanced T cell. The T cell can enhance an immune response to cancer, and is useful in an immunotherapy effective for cancer and the treatment or prevention of infectious diseases and autoimmune diseases.

Method for enhancing a function of a T cell

Disclosed is a cell which can express a non-natural oligomeric protein, which has, introduced therein, a gene encoding an exogenous polypeptide corresponding to at least one endogenous polypeptide constituting a natural oligomeric protein, and in which the expression of the endogenous polypeptide is inhibited.

Method for expression of specific gene

The present invention relates to a T lymphocyte having an activity to induce a T lymphocyte recognizing an antigen and a technique to use the T lymphocyte.

Cytotoxic T lymphocyte

Provided are a chimeric antigen receptor comprising an extracellular domain capable of binding to an antigen, a transmembrane domain and at least one intracellular domain, the chimeric antigen receptor being characterized in that an intracellular domain of a glucocorticoid-induced tumor necrosis factor receptor (GITR) is contained as the intracellular domain; a nucleic acid encoding the chimeric antigen receptor; a cell expressing the chimeric antigen receptor; and a method for producing the cell.

Chimeric antigen receptor

Disclosed are: a cell capable of expressing an exogenous GITRL or an exogenous GITRL derivative; a method for producing the cell; a therapeutic or prophylactic agent comprising the cell as an active ingredient; use of the cell in the manufacture of a therapeutic or prophylactic agent; a method comprising a step of administering the cell to a subject; a viral vector carrying a gene encoding a GITRL or a GITRL derivative; a therapeutic or prophylactic agent comprising the viral vector as an active ingredient; use of the viral vector in the manufacture of a therapeutic or prophylactic agent; and a method comprising a step of administering the viral vector to a subject.

Cell capable of expressing exogenous GITR ligand

Growing community of inventors

Tsu, Japan

Hiroshi Shiku